bioecon Member area
Technology · Health & biomedicine / Diagnostics & medtech

Alveolus-on-Chip (Breathing Lung-on-Chip)

Micro-engineered biomimetic organ-on-chip platforms containing micro-machined porous elastomeric membranes lined with primary human alveolar epithelial and microvascular endothelial cells, subjected to cyclic pneumatic stretching to model lung respiration mechanics.

1 · What it gives

Alveolus-on-Chip (Breathing Lung-on-Chip) represents a revolutionary paradigm shift in translational pharmacology, disease modeling, and preclinical safety testing, bridging the stark translational divide between static two-dimensional cell monolayers and animal models. By reconstituting three-dimensional cellular architectures, tissue-tissue interfaces, and dynamic continuous fluidic shear in microengineered polydimethylsiloxane (PDMS) or cyclic olefin copolymer (COC) chips, the technology captures human-relevant organotypic physiology. These microphysiological systems (MPS) replicate organ-level multicellular communication, barrier integrity, and metabolic biotransformation.

The industrial platform integrates patient-derived stem or primary cells (adult stem cells or induced pluripotent stem cells iPSCs), extracellular matrix hydrogel scaffolding (such as Matrigel or synthetic hydrogels), and automated microfluidic actuation. Multi-organ microfluidic networks establish physiological vascular flow, mechanical cyclic strain (e.g., breathing lung-on-chip), and in-line transepithelial electrical resistance (TEER) barrier assessment. Analytical screening leverages confocal high-content imaging (HCS), secretome mass spectrometry, and single-cell RNA sequencing to quantify compound efficacy, pharmacokinetic-pharmacodynamic (PK/PD) parameters, and organ-specific toxicities with unprecedented predictive fidelity.

The key directions of this technology are:

  1. Microfluidic Device Microfabrication & Interfacing in Alveolus-on-Chip (Breathing Lung-on-Chip): Precision soft lithography and injection molding of biocompatible, low-sorption cyclic olefin polymer chips supporting dual microfluidic channels separated by porous ECM-coated membranes.
  2. Patient-Derived Multi-Cellular Spheroid & Organoid Biobanking: Standardizing the expansion of patient-derived organoid (PDO) biobanks with defined genetic lineages, preserving patient-specific drug response profiles.
  3. Multi-Organ Microphysiological Vascular Coupling: Interconnecting multiple organ compartments (e.g., gut-liver-kidney) via common recirculating endothelialized vascular channels to model systemic drug metabolism and multi-organ toxicity.
  4. High-Content Automated Phenotypic Screening: Automated confocal 3D image acquisition with machine-learning segmentation to evaluate organoid morphology, lumen integrity, and apoptosis kinetics at high throughput.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Human iPSC / Primary Cell Isolation & Sourcing│
│  (Patient biopsies, HLA-typed iPSC banks, differentiation)
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Chip Microfabrication & Membrane Functionalization│
│  (Cyclic olefin injection molding, ECM protein coating)│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: 3D Micro-Seeding & Air-Liquid / Fluidic Flow  │
│  (Co-culture seeding, programmable micro-perfusion)    │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: In-Line Barrier Integrity & Multi-Organ Run   │
│  (Real-time TEER sensing, cyclic vacuum mechanical stretch)
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Automated High-Content Imaging & Multi-Omics  │
│  (Confocal 3D segmentation, secretome mass spectrometry)
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Cell Sourcing & Stem Cell DifferentiationDerivation, banking, and lineage-specific differentiation of human iPSCs or primary tissue progenitor cells.In: Cryopreserved stem cells, differentiation media, ECM.
Out: High-purity specialized organotypic target cell populations.
Microfluidic Chip Fabrication & Surface ActivationPrecision manufacturing of microchannel cartridges and covalent surface functionalization with laminin or collagen.In: COC/PDMS polymers, porous polyester membranes, ECM.
Out: Surface-modified, sterile microfluidic chip assemblies.
Cell Seeding & Co-Culture Micro-PerfusionCompartmentalized introduction of parenchymal, stromal, and vascular endothelial cells followed by flow initiation.In: Differentiated cells, hydrogel matrix, microfluidic pump.
Out: Vascularized 3D tissue architectures within chip channels.
Dynamic Maturation & In-Line Barrier SensingContinuous fluidic perfusion, cyclic mechanical deformation, and continuous TEER electrical barrier monitoring.In: Recirculating cell culture media, micro-pumps, TEER electrodes.
Out: Physiologically matured organ-on-chip test specimens (>500 Ohm*cm2).
Pharmacological Profiling & Data GenerationExposure to drug candidates, dynamic metabolite sampling, 3D confocal fluorescence imaging, and bioinformatic scoring.In: Test compounds, analytical reagents, HCS automated microscope.
Out: Validated human-predictive efficacy and toxicological dossier.

Cross-cutting technologies of the sector:

  • Transepithelial Electrical Resistance (TEER) Monitoring: In-line impedance micro-electrodes providing continuous non-invasive measurement of epithelial/endothelial tight junction integrity.
  • Automated 3D High-Content Confocal Metrology: Volumetric optical reconstruction quantifying lumen formation, cell viability, and cellular heterogeneity across microfluidic arrays.

2 · What it replaces 3 · matched by industry

3 · How to implement 4 steps

  1. 1
    Micro-porous flexible membrane fabrication
    Precision molding 1-3 µm pore polydimethylsiloxane or bio-degradable collagen membranes with uniform cross-sectional thickness.
  2. 2
    Alveolar-capillary bilayer co-culturing
    Seeding human primary alveolar type I/II epithelial cells on the apical side and pulmonary microvascular endothelial cells on the basolateral side.
  3. 3
    Cyclic biomimetic vacuum respiration actuation
    Applying cyclic negative air pressure pulses (0.2 Hz, 5-15% linear strain) into flanking vacuum chambers to mimic breathing kinematics.
  4. 4
    Aerosol exposure and barrier permeability testing
    Exposing the apical air-liquid interface to nebulized therapeutics, aerosols, or respiratory pathogens while measuring transepithelial electrical resistance (TEER).

4 · Who delivers

Matched suppliers (matched automatically)

Gro-MedIndiaProduceractive
Galuku Lanka exports pvt LtdSri LankaProduceractive
aspira coEgyptProduceractive
Accsys TechnologiesNetherlandsProduceractive
Azaki Food InternasionalIndonesiaProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Emulate Bio🇺🇸 United StatesOrgan-Chip Microfluidic Human Emulation SystemStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Miltenyi Biotec🇩🇪 GermanyCliniMACS Prodigy Automated ProcessingStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Lonza Cell & Gene🇨🇭 SwitzerlandCocoon Closed Manufacturing PlatformStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Cytiva🇺🇸 United StatesXuri Cell Expansion Bioreactors & SefiaStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
WuXi Advanced Therapies🇨🇳 ChinaViral Vector Testing & Analytical DevelopmentStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Sartorius Stedim Biotech🇩🇪 GermanyAmbr Bioreactors & Process PAT SystemsStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Thermo Fisher Scientific🇺🇸 United StatesGibco CTS Cell Therapy MediaStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

FDA Modernization Act 2.0, NIH Microphysiological Systems consortia#

  • FDA Modernization Act 2.0 Implementation: Statutory authorization enabling organ-on-chip and human organoid data for Alveolus-on-Chip (Breathing Lung-on-Chip) to replace or complement animal safety testing in IND submissions.
  • NCATS Microphysiological Systems Program: Multi-center NIH partnerships standardizing MPS reproducibility, inter-laboratory qualification, and clinical translation.
  • Big Pharma Testing Consortia: Direct integration of multi-organ MPS platforms into early drug discovery ADME-Tox screening cascades across major US biopharma.

European Union

EUROoCS consortia, 3Rs animal replacement frameworks, EMA guidelines#

  • European Organ-on-Chip Society (EUROoCS): Harmonizing technical interfaces, open-source standards, and reproducibility criteria across European academic and CDMO centers.
  • EU 3Rs Directive (2010/63/EU): Strong regulatory pressure to reduce, refine, and replace animal experimentation driving proactive adoption of human-relevant MPS systems.
  • Horizon Europe Collaborative Frameworks: Multi-national consortia developing disease-specific organ-on-chip platforms for neurodegenerative and immune-mediated diseases.

China

National high-tech R&D programs, NMPA organoid standards, regional chips#

  • National Key R&D Program for Organoids & MPS: Direct state funding fostering domestic chips and organoid biobanks under 仿生呼吸机械拉伸肺泡微流控芯片(Alveolus-on-Chip).
  • NMPA Regulatory Science Initiative: Formulating technical standards and validation guidelines for organoid drug sensitivity testing in precision oncology.
  • Microfluidic Manufacturing Industrial Clusters: High-density biomedical manufacturing ecosystems across Shenzhen, Suzhou, and Shanghai producing medical-grade COC microchips.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Microfluidic Fluidic Architecture in Alveolus-on-Chip (Breathing Lung-on-Chip):
    • Cyclic olefin copolymer (COC) substrates with low non-specific small-molecule drug adsorption.
    • Porous track-etched membrane interfaces supporting physiologically relevant fluid shear stress (0.2–2 dyn/cm2).
  2. Organotypic Cellular Assembly:
    • Human iPSC-derived multicellular co-cultures containing parenchymal cells, primary microvascular endothelial cells, and tissue-resident macrophages.
    • Synthetic hydrogel extracellular matrices with tunable stiffness and matrix metalloproteinase (MMP) cleavage motifs.
  3. Integrated Analytical Sensing Suite:
    • Embedded thin-film gold microelectrodes delivering automated TEER resistance logging.
    • Microfluidic effluent fraction collection coupled directly to micro-flow LC-MS/MS for real-time drug metabolite profiling.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22